Tumor hypoxia and the progression of prostate cancer

被引：27

作者：

Anastasiadis A.G. ^{[1
]}

Stisser B.C. ^{[1
]}

Ghafar M.A. ^{[1
]}

Burchardt M. ^{[1
]}

Buttyan R. ^{[1
]}

机构：

[1] Department of Urology, Columbia University, Herbert Irving Pavilion, 11th Floor, 161 Fort Washington Avenue, New York, 10032, NY

来源：

Current Urology Reports | 2002年 / 3卷 / 3期

关键词：

Prostate Cancer; Prostate Cancer Cell; Prostate Cancer Cell Line; Tumor Hypoxia; Vascular Endothelial Growth Factor Protein;

D O I：

10.1007/s11934-002-0068-6

中图分类号：

学科分类号：

摘要：

Tumor cell hypoxia is an innate environmental factor encountered during the development of many types of human tumors, including malignant prostate tumors. For prostate cancer, however, tumor cell hypoxia may be an even more critical element in tumor development and progression. Recent evidence suggests that androgenic steroids are important regulators of blood flow to prostate tumors and suppressors of tumor cell hypoxia. In addition, because prostate tumor cells are similar to other eukaryotic cells, they have the ability to respond to hypoxic conditions with drastic changes in gene expression mediated by the upregulation of a unique transcription factor, hypoxiainducible factor-1. This response increases cancer cells’ metabolic resistance to hypoxia, and also enhances the ability of prostate cancer cells to attract a more vigorous blood supply by upregulating the expression of pro-angiogenic factors. Because such changes would, in essence, increase the potential aggressiveness of affected prostate cancer cells, it is clear that tumor hypoxia has the potential for being a very important factor in prostate cancer cell biology. This review focuses on recent studies regarding the occurrence and potential role of hypoxia in prostate cancer, including hypoxia-inducible factor-1 and its related signaling pathways. © 2002, Current Science Inc.

引用

页码：222 / 228

页数：6

共 40 条

[1] Greenlee R.T., Murray T., Bolden S., Wingo P.A., Cancer statistics, 2000, CA Cancer J Clin, 50, pp. 7-33, (2000)
[2] Isaacs J.T., Lundmo P.I., Berges R., Et al., Androgen regulation of programmed death of normal and malignant prostatic cells, J Androl, 13, pp. 457-464, (1992)
[3] Buttyan R., Shabsigh A., Perlman H., Colombel M., Regulation of apoptosis in the prostate gland by androgenic steroids, Trends Endocrinol Metab, 10, pp. 47-54, (1999)
[4] Shabsigh A., Ghafar M.A., de la Taille A., Et al., Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland, J Cell Biochem, 81, pp. 437-444, (2001)
[5] Folkman J., Angiogenesis in cancer, vascular, rheumatoid, and other disease, Nat Med, 1, pp. 27-31, (1995)
[6] Semenza G.L., Expression of hypoxia-inducible Factor 1: mechanisms and consequences, Biochem Pharmacol, 59, pp. 47-53, (2000)
[7] Nordsmark M., Overgaard M., Overgaard J., Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck, Radiother Oncol, 41, pp. 31-39, (1996)
[8] Hockel M., Schlenger K., Aral B., Et al., Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix, Cancer Res, 56, pp. 4509-4515, (1996)
[9] Brizel D.M., Scully S.P., Harrelson J.M., Et al., Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma, Cancer Res, 56, pp. 941-943, (1996)
[10] Movsas B., Chapman J.D., Horwitz E.M., Et al., Hypoxic regions exist in human prostate carcinoma, Urology, 53, pp. 11-18, (1999)

← 1 2 3 4 →